We report two cases of type 1 diabetes mellitus (T1DM) which developed after interferon (IFN) therapy for chronic hepatitis C. The patients had experienced abrupt hyperglycemia with positive anti-glutamic acid decarboxylase antibodies, resulting in initiation of insulin therapy. In one case, insulin therapy could be discontinued because endogenous insulin secretion was preserved at the onset and pancreatic β cell function was recovered thereafter. In the other case with Hashimoto's thyroiditis and Sjögren's syndrome, continuation of insulin therapy was necessary because blood glucose levels were unstably controlled. Lasting autoimmunity superior to immunosuppressive mechanism may be associated with distinct clinical courses in these cases.
Introduction
Interferon (IFN) is a cytokine with various biological actions such as antiviral and anti-tumoral activity; it regulates immune responses and cell differentiation. Type 1 interferons (IFN-α, ω, β) enhance cell-mediated immunity by increasing the expression of MHC class 1 antigens and augment cytotoxic activity of NK and CD8 + cells. However, the excessive actions can trigger the onset of autoimmune diseases (1) .
Combined administration of peg-IFN with ribavirin is a standard therapy of chronic hepatitis C, whereas IFN therapy can induce type 1 diabetes mellitus (T1DM). We encountered 2 cases of T1DM provoked by IFN therapy for chronic hepatitis C. The cases resulted in different clinical courses with regard to insulin requirement for management of diabetes. 
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to our hospital because she had repeated hypoglycemic attacks. She did not have DM prior to IFN therapy. She was 142.6 cm tall and weighed 40.5 kg (BMI 19.9 kg/m 2 ). She also suffered from dry eyes, difficulty in swallowing, and arthralgia of bilateral fingers and knees without swelling of the joints. In the laboratory data shown in Table 1 , S-and U-CPRs were low. GAD Abs were positive. Liver transaminases were within normal range and HCV-RNA was not detected although lymphopenia was found. Rheumatoid factor and anti-SSA/SSB antibodies were all positive. Sjögren's syndrome was finally diagnosed based on decreased secretion of saliva and tears, ultrasonographic findings of chronic inflammation in salivary glands, and infiltration of chronic inflammatory cells in biopsy specimen of the labial glands. Hashimoto's thyroiditis (HT) with adenomatous goitor was also diagnosed based on positive TPO and Tg Abs and diffuse swollen thyroid with nodules in ultrasonography. HLA DNA typing revealed DRB1*0901, DQB1*0303. Her clinical course is shown in Fig. 2 . She received treatment with insulin aspart (14 U/day soon before meals) and NPH insulin (12 U/day before breakfast and bedtime), resulting in stable blood glucose levels at 150 to 190 mg/dL before meals. However, control of blood glucose levels after discharge was unstable again because of repeated hyperglycemia and hypoglycemia, leading to high HbA1C levels. To improve the condition NPH insulin was replaced with insulin glargine due to the improved efficacy of insulin glargine compared with NPH insulin as intensive replacement of basal insulin in patients with difficult glycemic control with NPH insulin. Titers of GAD Abs were temporally reduced to 656 U/mL, but became elevated again to 1,150 U/mL 17 months after admission. (4) . However, the onset of T1DM is less frequent than type 2 DM in chronic HCV infection (5) . IFN therapy for chronic hepatitis C can increase the risk for developing DM. Fabris et al (6) noted that the positivity rate of pancreaticassociated autoantibodies was 3% before IFN therapy, whereas rose to 7% after therapy. IFN-α is a primary initiator of the type 1 diabetic process not only in mice but also in humans (7) .
Discussion
Chronic HCV infection causes a variety of autoimmune manifestations such as autoimmune thyroid diseases (ATD) and Sjögren's syndrome (SS). HCV-RNA was detected in thyroid and salivary gland tissues from patients with chronic HCV infection, indicating HCV per se has some role in the formation of diseases (2, 3). HCV is also present in human pancreatic β cells and it is associated with morphological cell changes and reduced glucose-stimulated insulin release
The correlation between IFN therapy-induced T1DM and HLA class II alleles has been reported. HLA haplotypes associated with susceptibility to T1DM were found in 44-89% of the patients with IFN therapy-related T1DM (6, 8) . The susceptibility is linked to DRB1*0405-DQB1*0401, DRB1 *0802-DQB1*0302, and DRB1*0901-DQB1*0303 in the almost all Japanese patients of IFN therapy-related T1 DM (9) . In the present cases, the patients had the susceptible HLA alleles although the haplotypes were not been examined, and overt DM with positive GAD Abs was first found after treatment with IFN-α. The organ-specific autoantibodies associated with ATD and SS were also detected in Case 2. It was not clear whether these autoantibodies were detected before treatment. In a previous report, patients who were initially positive for organ-specific autoantibodies and those who seroconverted were at high risk of developing clinical autoimmune diseases after treatment with IFN-α (10) . However, a group showed that only 2 (22.2%) of 9 patients with T1DM caused by treatment with IFN-α and ribavirin had T1DM-associated autoantibodies before treatment. In addition, TPO Abs were negative in all patients who developed T1DM and one (0.5%) of them had hypothyroidism due to thyroiditis (8) . Therefore the occurrence of T1DM does not seem to be always predicted through autoantibodies detected before treatment with IFN.
The characteristics of the two cases are shown in Table 2 . Each case followed a distinct clinical course. It is interesting T a b l e 2 . Cl i n i c a l F e a t u r e s o f Ca s e s Case that endogenous insulin secretion was comparatively preserved at the onset of DM and insulin therapy could be discontinued although titers of GAD Abs were so high in Case 1. Eight (25.8%) of 31 patients with T1DM due to treatment with IFN received insulin therapy temporally in one report (6) , but all of the patients did in another report (8) . HLA serotype A24, which is known to be connected with progressive destruction of pancreatic β cells, was detected in the present Case 1, but β cell function was not abolished. There are some reports on clinical remission of IFN therapy-induced T1DM in patients with chronic hepatitis after insulin therapy (11, 12) . However, the mechanism was not elucidated. An immunological mechanism is important for clinical remission on T1DM. Interleukin-10 (IL-10), which suppresses the helper T cell function, may influence the disease remission. IL-10 was predominantly secreted in peripheral blood mononuclear cells, especially CD4 + cells, from patients of T1DM with complete recovery of β cell function (13) . We also believe that estrogen may be another considerable factor of preserving β cell function. 17, βestradiol (E2) not only directly protects β cells from apoptosis and prevents insulin-deficient DM but also drives the ex-pansion of CD4 + CD25 + regulatory T cells, which are essential to suppress autoreactive effector T cell function (14, 15) . In the premenopausal patient in Case 1, β cells may be preserved by secretion of IL-10 and/or estrogen, whereas in the postmenopausal patient with other organ-specific autoimmunity as in Case 2, lasting autoimmune responses superior to immunosuppressive actions of both may be associated with poor clinical remission. We need to verify the relationship between clinical remission and secretion of IL-10 and/or estrogen by case accumulation because there are not any previous reports to show it. T1DM is an important adverse effect of IFN therapy for chronic HCV infection which affects the patients' quality of life. Currently there are no reliable markers for predicting the development and progression of IFN therapy-induced T1DM. Therefore, we should pay close attention to the appearance of islet-associated autoantibodies and perform the estimation of endogenous insulin secretion and glucose tolerance before IFN therapy or during its interruption for the early detection of the onset of T1DM. Also, in the treatment of T1DM it may be necessary to proceed with consideration of the immunological or hormonal status of the patient.
